Survival Prediction for Pancreatic Cancer Patients Receiving Gemcitabine Treatment
Open Access
- 1 April 2010
- journal article
- research article
- Published by Elsevier BV in Molecular & Cellular Proteomics
- Vol. 9 (4), 695-704
- https://doi.org/10.1074/mcp.m900234-mcp200
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Identification of a Predictive Biomarker for Hematologic Toxicities of GemcitabineJournal of Clinical Oncology, 2009
- Large‐scale quantitative clinical proteomics by label‐free liquid chromatography and mass spectrometryCancer Science, 2009
- Modelling prognostic factors in advanced pancreatic cancerBritish Journal of Cancer, 2008
- Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19‐9 levels in pancreatic cancerProteomics, 2008
- Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional StudyJNCI Journal of the National Cancer Institute, 2007
- Possible Detection of Pancreatic Cancer by Plasma Protein ProfilingCancer Research, 2005
- Possible Prediction of Chemoradiosensitivity of Esophageal Cancer by Serum Protein ProfilingClinical Cancer Research, 2005
- Poly(ADP-Ribose) Polymerase-1 Is a Component of the Oncogenic T-Cell Factor-4/β-Catenin ComplexGastroenterology, 2005
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003
- Alpha1‐antitrypsin and survival in pancreatic cancerInternational Journal of Cancer, 1990